Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
NWE headed into the week with its sharpest one-week gain in recent memory, up 8.2% to close at $73.97 on Wednesday, and the options market is telling a story that cuts against any notion of defensive caution.
The clearest signal is in the options book. Call demand has overwhelmed puts to a degree well outside the normal range: the put/call ratio dropped to 0.15, more than 1.2 standard deviations below its 20-day average of 0.21, and near the lowest reading of the past year. That is unusually one-sided for a regulated utility. The lending market reinforces the picture of a stock with limited short conviction. Availability is effectively unlimited, with roughly 60 million shares available to borrow against fewer than two million shorted, an availability ratio of over 6,000%. Short interest at 3.2% of the free float is itself unremarkable, and the ORTEX short score has drifted lower all week, from 38.0 to 37.0, its softest reading in the 10-day window. Borrowing costs rose 25% over the week to 0.56%, but from a near-zero base, the absolute level remains trivial. There is no short squeeze dynamic here, and no crowded short to unwind.
The Street sits in a holding pattern, though with a faint tilt toward caution on valuation. Barclays, maintaining its Overweight, trimmed its target from $73 to $70 on October 6, one day before Wednesday's close at $73.97. That means the stock has already traded through Barclays' new target. JP Morgan, at Neutral, set its target at $73 in September, also now below the current price. Wells Fargo, at Equal-Weight, is at $70. The consensus mean target of $72.75 implies a modest pullback from here. None of these are aggressive calls in either direction. The factor profile is similarly middling: EPS momentum ranks in the 30s over both 30 and 90-day windows, value screens are unremarkable, and the short score rank of 43 is near the median. The one standout is the dividend score, ranked at the 94th percentile, relevant given the stock's identity as an income holding.
Wednesday's move stands out even against NWE's closest peer. BKH gained 7.2% on the day and 8.2% on the week, a near-identical move given the two names carry a 99% price correlation. Both moved in lockstep. By contrast, AVA rose just 0.4% over the week, and AEE added 2.0%. The sector-wide nature of the BKH-NWE surge points to a macro or rate-related catalyst rather than anything company-specific, though what that catalyst was is not specified in the data.
Insider activity on October 1 saw eight directors receive stock grants at $68.38 per share. These were compensation awards (transaction code A), not open-market purchases, so they carry limited informational value as a signal of conviction. Net open-market buying over the prior 90 days was zero. BlackRock remains the dominant holder at around 14.7% of shares, having added 789,000 shares in its most recently reported period. No 13D activist is on the register.
Q3 results are due October 27, nineteen days away. The two most recent quarterly prints each produced a negative day-one reaction: down 2.6% and down 3.5% respectively. With the stock now trading above every major analyst's price target, and call positioning at its most stretched in a year, what happens to that options skew in the final three weeks before the print is the sharpest thing to watch.
See the live data behind this article on ORTEX.
Open NWE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
